Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: A meta-analysis

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1307-1311

  Xu, Yipeng ^a   Zhu, Shaoxing ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Meta analysis; Polymorphism; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ALLELE; ARTICLE; CANCER RISK; CAUCASIAN; CHROMOSOME 6P; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EXON; GENETIC POLYMORPHISM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

ALLELES; CASE-CONTROL STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898919193     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1173-5     Document Type: Article

References (27)

1. Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-21. (Pubitemid 351671887)
2. Schroder FH, Hugosson J, RoobolMJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-90.
3. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300-18. quiz 323-305.
4. Amankwah EK, Sellers TA, Park JY. Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis. 2012;33:1259-69.
5. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, et al. Identification of 23 new prostate cancer susceptibility loci using the icogs custom genotyping array. Nat Genet. 2013;45:385-91. 391e381-382.
6. Zhang H, Li L, Xu Y. CYP1B1 polymorphisms and susceptibility to prostate cancer: a meta-analysis. PLoS One. 2013;8:e68634.
7. Yu Z, Li Z, Cai B, Wang Z, Gan W, Chen H, et al. Association between the GSTP1 Ile105Val polymorphism and prostate cancer risk: a systematic review and meta-analysis. Tumour Biol. 2013;34:1855-63.
8. Wang K, Peng HL, Li LK. Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev. 2012;13:5665-9.
9. Lee RJ, Smith MR. Targeting met and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 2013;19:90-8.
10. Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol. 2013;34:1895-9.
11. Hansen TF, Jakobsen A. Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics. 2011;12:1681-93.
12. Hu K, Zhang Y, Wang R, Li G, Zhang D. Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies. Twin Res Hum Genet. 2012;15:496-502.
13. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369-72. (Pubitemid 34651380)
14. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21-8. (Pubitemid 44485531)
15. Jacobs EJ, Hsing AW, Bain EB, Stevens VL, Wang Y, Chen J, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:972-7. (Pubitemid 351536431)
16. Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572-6.
17. Sfar S, Saad H, Mosbah F, Chouchane L. Synergistic effect and VEGF/HSP70-hom haplotype analysis: relationship to prostate cancer risk and clinical outcome. Hum Immunol. 2010;71:377-82.
18. VanCleave TT, Moore JH, Benford ML, Brock GN, Kalbfleisch T, Baumgartner RN, et al. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate. 2010;70:341-52.
19. Ianni M, Porcellini E, Carbone I, Potenzoni M, Pieri AM, Pastizzaro CD, et al. Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis. 2013;16:56-61.
20. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC. Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer. Urology. 2003;62:374-7.
21. Fukuda H, Tsuchiya N, Narita S, Kumazawa T, Horikawa Y, Inoue T, et al. Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. Oncol Rep. 2007;18:1155-63.
22. Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep. 2008;35:17-22.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. (Pubitemid 37088507)
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. (Pubitemid 17189972)
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
26. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563-84.
27. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873-87.